YG1702 is a potent ALDH18A1-specific inhibitor. YG1702 attenuates the growth of MYCN-amplified NB and down-regulates MYCN. YG1702 psically interacts with ALDH18A1 with a high affinity and might potentially affect its enzymatic activity.
YG1702 (intraperitoneal injection (I.P.), 45 mg/kg, once every 3 days, three times) inhibits the growth of the xenografts in tumor-bearing mice[1].
References:
[1]. Guo YF, et al. Inhibition of the ALDH18A1-MYCN positive feedback loop attenuates MYCN-amplified neuroblastoma growth. Sci Transl Med. 2020 Feb 19;12(531):eaax8694.